Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Case 98% Improvement Relative Risk c19vitamind.com van Helmond et al. NCT04596657 Vitamin D Prophylaxis Favors vitamin D Favors control
van Helmond, 3,082 patient vitamin D prophylaxis study: 98% fewer cases [p=0.07] https://c19p.org/vanhelmond
copied to clipboard
Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-Like Illness in Healthcare Workers: A Randomized Clinical Trial
van Helmond et al., medRxiv, doi:10.1101/2022.09.16.22280047 (Preprint), NCT04596657 (history)
17 Sep 2022    Source   PDF   Share   Tweet
Prospective prophylaxis trial with 255 healthcare workers taking vitamin D and 2,827 controls, showing significantly lower influenza-like illness with treatment, and lower COVID-19 cases, without statistical significance. While the intervention and control groups were initially randomized, exclusions were only processed in the treatment arm.
risk of case, 97.5% lower, RR 0.02, p = 0.07, treatment 0 of 255 (0.0%), control 36 of 2,827 (1.3%), NNT 79, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
van Helmond et al., 17 Sep 2022, prospective, USA, preprint, 14 authors, study period 27 October, 2020 - 31 January, 2021, dosage 5,000IU daily, trial NCT04596657 (history).
Contact: mitrev-ludmil@cooperhealth.edu, vanhelmond-noud@cooperhealth.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit